Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database.
MacDonald
Michael R
MR
Golden Jubilee National Hospital, Glasgow, Scotland. finlay.mcalister@ualberta.ca
Eurich
Dean T
DT
Majumdar
Sumit R
SR
Lewsey
James D
JD
Bhagra
Sai
S
Jhund
Pardeep S
PS
Petrie
Mark C
MC
McMurray
John J V
JJ
Petrie
John R
JR
McAlister
Finlay A
FA
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D004077:Digoxin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D004077:Digoxin; D008687:Metformin; D001241:Aspirin